Lotus Eye Hospital Intrinsic Value
Lotus Eye Hospital intrinsic value. Lotus Eye Hospital (LOTUSEYE) median intrinsic value is ₹34.61 from 8 valuation models (range ₹29–₹46), vs current price ₹115.37 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Lotus Eye Hospital share price screener.
LOTUSEYE Valuation Methods Summary — DCF, Graham Number & P/E
Lotus Eye Hospital intrinsic value across 8 models vs current price ₹115.37 — upside/downside and value range per method. Read LOTUSEYE dividend yield for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹34.61 | ₹27.69 - ₹41.53 | -70.0% | EPS: ₹0.10, Sector P/E: 12x |
| Book Value Method | asset | ₹28.57 | ₹25.71 - ₹31.43 | -75.2% | Book Value/Share: ₹28.57, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹34.61 | ₹31.15 - ₹38.07 | -70.0% | Revenue/Share: ₹28.10, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹46.15 | ₹41.53 - ₹50.77 | -60.0% | EBITDA: ₹6.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹46.15 | ₹36.92 - ₹55.38 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹34.61 | ₹31.15 - ₹38.07 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹34.61 | ₹31.15 - ₹38.07 | -70.0% | Revenue Growth: 5.3%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹34.61 | ₹31.15 - ₹38.07 | -70.0% | EPS: ₹0.10, BVPS: ₹28.57 |
LOTUSEYE Intrinsic Value vs Market Price — All Valuation Models
Lotus Eye Hospital fair value range ₹29–₹46 vs current market price ₹115.37 across 8 valuation models. Compare with LOTUSEYE DCF valuation to assess whether the stock is under or overvalued.
LOTUSEYE Intrinsic Value Analysis — Undervalued or Overvalued?
Lotus Eye Hospital median intrinsic value ₹34.61, current price ₹115.37 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of LOTUSEYE?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Lotus Eye Hospital (LOTUSEYE) is ₹34.61 (median value). With the current market price of ₹115.37, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹28.57 to ₹46.15, indicating ₹28.57 - ₹46.15.
Is LOTUSEYE undervalued or overvalued?
Based on our multi-method analysis, Lotus Eye Hospital (LOTUSEYE) appears to be trading above calculated value by approximately 70.0%.
LOTUSEYE Financial Health — Key Ratios vs Industry Benchmarks
Lotus Eye Hospital financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.85 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.71x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
LOTUSEYE Cash Flow Quality — Operating & Free Cash Flow
Lotus Eye Hospital operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹3 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹3 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹6 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹4 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |